Study details
Enrolling now
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
M.D. Anderson Cancer Center
NCT IDNCT05929612ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
50
Study length
about 4.4 years
Ages
18+
Locations
1 site in TX
About this study
This trial is testing if response-adapted, ultra-low dose radiation therapy can help to control marginal zone lymphoma (MZL). Participants first receive lower doses of radiation therapy and then, based on how the disease responds, may receive higher doses after that.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Ultra Low Dose 4 Gy Radiation
PhasePhase 2
Primary goalIncidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Procedures
radiation
Body systems
Oncology